Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Roll-over Protocol for Patients Benefiting From Continued Treatment
NCT01742299Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2013
- Primary completion
- Apr 2026
- Countries
- 11
01
Overview
Phase 4, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST) and chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: Frequency and Severity of Adverse Events and Serious Adverse Events at 157 months. Started Mar 2013; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01742299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01742299.